Switching to brelovitug for chronic hepatitis D patients on bulevirtide
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been taking bulevirtide for chronic hepatitis D for at least 6 months
- You are willing to take a hepatitis B medicine (TDF, TAF, or ETV) during the study
- You have a hepatitis D virus level of at least 100 IU/mL at screening
- You do not have advanced liver disease (like severe scarring, fluid in the belly, or bleeding from veins in the esophagus)
- You do not have active hepatitis C or HIV, or a history of liver cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
This study looks at how well the drug bulevirtide (BLV) works over a long period for people with hepatitis D (HDV) and liver scarring that is still under control (compensated cirrhosis). It may help you if you have been taking BLV alone and want to see how your liver and health have been doing.
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
Hear when a new Chronic Hepatitis D trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.